Loading...
Loading...
LQDA| Name | Value |
|---|---|
| Revenues | 4.4M |
| Cost of Revenue | 1.6M |
| Gross Profit | 2.9M |
| Operating Expense | 32.1M |
| Operating I/L | -29.2M |
| Other Income/Expense | 6.0M |
| Interest Income | 1.8M |
| Pretax | -23.2M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -23.2M |
Liquidia Corporation is a biopharmaceutical company that develops, manufactures, and commercializes products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. The company also distributes generic treprostinil injection in the United States.
